Skip to main content
. Author manuscript; available in PMC: 2024 Feb 4.
Published before final editing as: Gastroenterology. 2022 Aug 4:S0016-5085(22)00829-0. doi: 10.1053/j.gastro.2022.07.053

Fig.3.

Fig.3.

Modulation of RvD1 synthesis via Tlr4-Lox5 pathway in colonic mucosa. (A) ELISA data show the level of RvD1 in the colonic tissue from wild-type (WT, n=8), Lox12 KO (Lox 12, n=4), Lox5 KO (Lox 5, n=4), WT mice pretreated with MK886 (1 mg/kg, n=6), Tlr2 KO (n=4) and Tlr4 KO mice (n=13). *, P<0.05 ANOVA with Bonferoni post-hock test. (B) VMR to colorectal distention data show that Lox12 KO (n=4), Lox5 KO (n=4) and wild-type pretreated with MK886 mice (n=6) exhibited hypersensitivity when compared to wild-type (n=6). Results are expressed as mean ± SEM, ***, P<0.001 and **, P<0.01 from WT. (C) VMR to colorectal distention shows that intracolonic administration of IBS-FS failed to generate visceral hypersensitivity in Tlr4 KO mice (n=5), when compared to wild-type (n=8). Results are expressed as mean ± SEM, ***, P<0.001; **, P<0.01 and *, P<0.05 from WT+HC-FS.